Dr. Helmuth van Es
AC member
Dr. Helmuth van Es is a passionate biomedical entrepreneur with more than 30 years of experience. In 2015 he co-founded Citryll, a Curie Capita portfolio company, for which he now serves as a board Director. Dr. van Es started his career at Crucell, was co-founder of Galapagos as the Head of Science. In 2006 he set up the European R&D site for Stem Cell Innovations as CSO and started several CNS drug discovery partnerships with pharma and US patient organizations. After SCI he co-founded and was previously CSO and Board member of Audion Therapeutics BV, aiming to develop therapies for acquired hearing loss. He is co-founder, former CBO, former chair, and until December 2023 non-executive board member of Antabio based in France, UK, USA. Antabio is a clinical stage company developing a new generation of anti-bacterials. He co-founded UK based Effecta Pharma Ltd with Paul Edwards, former VP Medicinal Chemistry Boehringer Ingelheim. Until mid 2019 he was part of the Hifibio advisory board.
Our other team members
We are a venture capital firm specializing in seed investments for innovative early-stage companies. Curie Capital typically takes on the role of lead investor. Our team comprises life science experts and business analysts who offer guidance to life science companies throughout the entire research and development process.
Han de Groot
Partner
Mariette van der Velden
Partner
Thom Frielink
Associate
